{
  "table_name": "patent_use_codes_30",
  "table_fullname": "bigquery-public-data.ebi_chembl.patent_use_codes_30",
  "column_names": [
    "code_utilisation_brevet",
    "définition"
  ],
  "column_types": [
    "STRING",
    "STRING"
  ],
  "nested_column_names": [
    "code_utilisation_brevet",
    "définition"
  ],
  "nested_column_types": [
    "STRING",
    "STRING"
  ],
  "description": [
    "Clé primaire. Code d'utilisation de brevet de l'FDA Orange Book",
    "Définition du code d'utilisation de brevet, de l'FDA Orange Book."
  ],
  "sample_rows": [
    {
      "code_utilisation_brevet": "U-3023",
      "définition": "TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G-&gt;A, AND 3849+10KBC-&gt;T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546"
    },
    {
      "code_utilisation_brevet": "U-3128",
      "définition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM &amp; VABORBACTAM AS SPECIFIED"
    },
    {
      "code_utilisation_brevet": "U-3022",
      "définition": "TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G-&gt;A, &amp; 3849+10KBC-&gt;T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546"
    },
    {
      "code_utilisation_brevet": "U-158",
      "définition": "ANGINA"
    },
    {
      "code_utilisation_brevet": "U-228",
      "définition": "ASTHMA"
    }
  ]
}